[Skip to Navigation]
April 14, 2021

Moving Beyond Medications That Act at the μ Receptor in the Treatment of Opioid Use Disorder

Author Affiliations
  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 3Harvard Medical School, McLean Hospital, Belmont, Massachusetts
JAMA Psychiatry. 2021;78(7):701-702. doi:10.1001/jamapsychiatry.2021.0259

The opioid crisis continues unabated during the COVID-19 pandemic. There is a need to explore novel treatments for opioid use disorder (OUD), given the devastation of more than 46 000 annual opioid-related overdose deaths1 and the medical and social toll of OUD. Life-saving pharmacotherapies for OUD are available (methadone, buprenorphine, and naltrexone) but are underused. Moreover, their effectiveness, while clear, leaves substantial room for improvement.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words